Preliminary determination of a molecular basis of chronic fatigue syndrome.
Preliminary determination of a molecular basis of chronic fatigue syndrome.
复制标题
慢性疲劳综合征的分子基础的初步确定。
DOI：
--
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
I. Klineberg
中科院分区：
文献类型：
--
作者：
N. McGregor;R. Dunstan;M. Zerbes;H. Butt;T. Roberts;I. Klineberg
慢性疲劳综合症（CFS/ME）是一种使人衰弱的疲劳疾病，其病因尚不清楚。我们研究了 20 名符合牛津和美国 CDC 定义的慢性疲劳综合症 (CFS) 患者，以及 45 名非 CFS 受试者。参与者填写了调查问卷，接受了临床检查，并收集了第一次晨尿样本，通过气相色谱-质谱法筛查代谢物排泄的变化。与非 CFS 患者相比，CFS 患者的尿液代谢物谱的多变量分析存在显着差异 (P < 0.004)。 CFS 患者的氨基羟基-N-甲基吡咯烷（P < 0.00003，称为慢性疲劳症状尿标志物 1，或 CFSUM1）、酪氨酸（P < 0.02）、β-丙氨酸（P < 0.02）、乌头酸（P < 0.05）和琥珀酸（P < 0.05）增加，并且未确定的减少 尿代谢物 CFSUM2 (P < 0.0007)、丙氨酸 (P < 0.005) 和谷氨酸 (P < 0.02)。通过判别函数分析发现，CFSUM1、β-丙氨酸和 CFSUM2 分别是区分 CFS 和非 CFS 受试者的第一、第二和第三最重要的代谢物。 CFSUM1 和 β-丙氨酸的丰度与症状发生率（分别为 P < 0.01 和 P < 0.001）、症状严重程度、核心 CFS 症状和 SCL-90-R 躯体化呈正相关（P < 0.00001），提示 CFS 的分子基础。
Chronic fatigue syndrome (CFS/ME) is a debilitating fatigue illness that has an unknown etiology. We studied 20 chronic fatigue syndrome (CFS) patients, who complied with the Oxford and American CDC definitions, and 45 non-CFS subjects. Participants completed questionnaires, were clinically examined, and had first morning urine specimens collected, which were screened by gas chromatography-mass spectrometry for changes in metabolite excretion. Multivariate analysis of the urinary metabolite profiles differed significantly in the CFS patients compared to the non-CFS patients (P < 0.004). The CFS patients had increases in aminohydroxy-N-methylpyrrolidine (P < 0.00003, referred to as chronic fatigue symptom urinary marker 1, or CFSUM1), tyrosine (P < 0.02), beta-alanine (P < 0.02), aconitic acid (P < 0.05), and succinic acid (P < 0.05) and reductions in an unidentified urinary metabolite, CFSUM2 (P < 0.0007), alanine (P < 0.005), and glutamic acid (P < 0.02). CFSUM1, beta-alanine, and CFSUM2 were found by discriminant function analysis to be the first, second, and third most important metabolites, respectively for discriminating between CFS and non-CFS subjects. The abundances of CFSUM1 and beta-alanine were positively correlated with symptom incidence (P < 0.01 and P < 0.001, respectively), symptom severity, core CFS symptoms, and SCL-90-R somatization (P < 0.00001), suggesting a molecular basis for CFS.